Osha Liang Files Amicus Brief for Biotechnology Innovation Organization

By: Dr. David S. Forman

日本語

日本語

简体中文

简体中文

繁體中文

繁體中文


Osha Liang Senior Counsel, Dr. David Forman, has filed an amicus brief for the Biotechnology Innovation Organization (BIO) at the U.S. Court of Appeals for the Federal Circuit in the appeal of Eli Lilly and Company v. Teva Parenteral Medicines, Inc. et al, the first case in which the Federal Circuit will apply its new rule governing divided infringement.  The briefing urged the Court to avoid narrowing its legal framework for analyzing divided infringement in a way in a way that might not apply to biotechnology method claims.

Dr. Forman focuses his practice on biotechnology and pharmaceuticals encompassing a variety of disciplines, including litigation, interferences, prosecution, appeals, and opinion work.

BIO is a trade association representing over 1,000 companies, academic institutions, and biotechnology centers.

Read the brief here: Eli Lilli v Teva_BIO Amicus Brief (English only)